week,disease,state,cases,deaths,cfr,report_date
,Measles,"Situation Report  
 
                                               September 2025  
Figure 12: Proportion Of Measles Samples With Good Turnaround Time, September 2025 
 
6 | P A G E",,,,
,Cholera,Cholera2,,,,
,COVID-19,"Acute Flaccid 
Paralysis (Afp) 2",,,,
,Lassa," Dissemination Of Reviewed Ipc Guideline
 Dissemination Of Health Facility Ipc Advisory
 Dissemination Of Lassa Fever Healthcare Worker
Advisories
 Identification And Assessment Of Treatment Centres
 Engagement With The Network Of Ipc Structures In
The States, The Orange Network, And Facilities On
Adherence To Standard Precautions
 Development Of Environmental Cleaning Guideline
 Piloting Of Epidemic Ready Primary Health Care
(Erphc) Program In Two States",,,,
,Lassa," Diagnosis Of All Samples In The Eight Lassa Fever
Testing Laboratories Across The Country
 External Quality Assurance (Eqa) Panel Preparation
For All Testing Laboratories Ongoing",,,,
,Lassa,"Infectionprevention
Andcontroland
Safeburial",,,,
,Lassa,Researchpillar,,,,
,Lassa,"Risk
Communication",,,,
,Lassa,Surveillance,,,,
,Lassa,Stateresponse,,,,
,Lassa,"Federalministryof
Environment",,,,
2023-W05,Lassa,"Infection 
Prevention And 
Control And Safe 
Burial",,,,2023-02-05
2023-W05,Lassa,Research Pillar,,,,2023-02-05
2023-W05,Lassa,"Risk 
Communication",,,,2023-02-05
2025-W48,Lassa,"  Dissemination Of Reviewed Ipc Guideline 
  Dissemination Of Health Facility Ipc Advisory  
  Dissemination Of Lassa Fever Healthcare Worker 
Advisories",,,,2025-11-24
2025-W48,Lassa,"  Diagnosis Of All Samples In The Five Lassa Fever Testing 
Laboratories Across The Country",,,,2025-11-24
2025-W48,Lassa,"  Implementation Of Nigeria Lassa Fever Epidemiological 
Study Supported By Cepi",,,,2025-11-24
2025-W48,Lassa,"  Implementation Of Targeted Risk Communication 
Activities In Most Affected States  
  Dissemination Of Media Content Including Press 
Releases, Tweets, Public Advisories Etc",,,,2025-11-24
2025-W48,Lassa,"  Multi-Sectoral Public Health Emergency Operation 
Centres (Pheoc)Activated In Affected States 
  Periodic Implementation Of Vector Control Measures In 
Edo And Ondo States",,,,2025-11-24
2025-W48,Lassa,"  Implementation Of Lassa Fever Environmental 
Response Campaign In High Burden States",,,,2025-11-24
2020-W21,Lassa,"  Dissemination Of Reviewed Ipc Guideline 
  Dissemination Of Health Facility Ipc Advisory  
  Dissemination Of Lassa Fever Healthcare Worker 
Advisories",,,,2020-05-24
2020-W21,Lassa,"  Lassa Fever Proposal Development Workshop For 
National Level Staff",,,,2020-05-24
2020-W21,Lassa,"  Implementation Of Targeted Risk Communication 
Activities In Most Affected States  
  Dissemination Of Media Content Including Press 
Releases, Tweets, Public Advisories Etc. 
  Lassa Fever Awareness And Prevention Campaign In 
Fct, Edo And Ondo Supported By Hypo",,,,2020-05-24
2020-W21,Lassa,"  Multi-Sectoral Public Health Emergency Operation 
Centres (Pheoc)Activated In Affected States  
  High Level Advocacy Visit By The Honourable Minister Of 
Health And Dg Ncdc To Kano State  
  Ondo State Governor Provided Two New Hilux Vehicle 
For Surveillance Activities And 20 Beds For Treatment 
Centre 
  Edo State Governor Inaugurated Lassa Fever Task Force 
To Tackle Lassa Fever In Edo State, Provided Ppe To 
Isth 
  Red Cross Currently Supporting Six High Burden States 
With Surveillance And Rodent Control And Risk 
Communications Activities",,,,2020-05-24
2020-W21,Lassa,"  Implementation Of Lassa Fever Environmental Response 
Campaign In High Burden States",,,,2020-05-24
"Lassa  fever  national  multi-partner,  multi-agency  Technical  Working  Group(TWG)  continues  to",Lassa,"Lassa  Fever  National  Multi-Partner,  Multi-Agency  Technical  Working  Group(Twg)  Continues  To",,,,2025-11-03
Lassa fever. Figure 1,Lassa,Lassa Fever. Figure 1,,,,
2025-W22,Meningitis,"Cerebrospinal Meningitis Outbreak In Nigeria 
 
Situation Report 
(As At 13Thapril, 2017)",,,,2025-06-01
2025-W01,Meningitis,"Cerebrospinal Meningitis Outbreak In Nigeria 
 
Situation Report 
 
(As At 6Thapril 2017)",,,,2025-01-02
2025-W45,Cholera,"Ongoing Finalization 
• 
Of Cholera 
Diagnostics 
Guidelines And Sop",,,,2025-11-05
2024-W32,Cholera,"Risk 
Communication",,,,2024-08-05
2024-W30,Cholera,"Risk 
Communication",,,,2024-07-22
2023-W05,Cholera,"• Continue Distribution Of 
Hygiene Kits To Affected 
States",,,,2023-02-04
2023-W05,Cholera,"• 
Continue Supporting 
Affected States With 
Essential Response 
Commodities",,,,2023-02-04
2024-W28,Cholera,"• Continue Distribution Of 
Hygiene Kits To Affected 
States",,,,2024-07-08
2024-W28,Cholera,"• 
Continue Supporting 
Affected States With 
Essential Response 
Commodities",,,,2024-07-08
2024-W26,Cholera,"Risk 
Communication",,,,2024-06-24
2024-W25,Cholera,"Risk 
Communication",,,,2024-06-17
2024-W24,Cholera,"Risk 
Communication",,,,2024-06-10
2024-W13,Cholera,"Risk 
Communication",,,,2024-03-25
2024-W09,Cholera,"Risk 
Communication",,,,2024-02-26
2024-W05,Cholera,"Risk 
Communication",,,,2024-01-29
2024-W01,Cholera,"Risk 
Communication",,,,2024-01-01
2025-W45,Cholera,"Risk 
Communication",,,,2025-11-03
2023-W44,Cholera,"Risk 
Communication",,,,2023-10-30
2025-W44,Cholera,Surveillance,,,,2025-11-02
2025-W45,Cholera,Surveillance,,,,2025-11-03
2025-W48,Cholera,Surveillance,,,,2025-11-26
,Cholera,Surveillance,,,,
2023-W13,Cholera,Surveillance,,,,2023-04-02
2023-W09,Cholera,Surveillance,,,,2023-03-05
2023-W01,Cholera,Surveillance,,,,2023-01-02
2023-W01,Cholera,"Risk
Communication",,,,2023-01-02
2023-W52,Cholera,Surveillance,,,,2023-01-01
2022-W47,Cholera,Surveillance,,,,2022-11-27
2022-W43,Cholera,Surveillance,,,,2022-10-30
2022-W39,Cholera,Surveillance,,,,2022-10-02
2022-W35,Cholera,Surveillance,,,,2022-09-04
2025-W47,Cholera,Surveillance,,,,2025-11-21
2022-W26,Cholera,Surveillance,,,,2022-07-03
2022-W21,Cholera,Surveillance,,,,2022-05-29
,Cholera,"L
A
B
O
R
A
T
O
R
Y",,,,
,Cholera,"Risk
Communication",,,,
2025-W32,Cholera,"L
O
G
I
T
I
C
S",,,,2025-08-06
2025-W32,Cholera,"Risk
Communication",,,,2025-08-06
2021-W52,Cholera,"•  Continuous  Construction  Of  Sanitation  And 
Hygiene  Facilities  With  Boreholes  In  Cholera 
Hotspots",,,,2021-12-27
2021-W52,Cholera,"Risk 
Communication",,,,2021-12-27
2021-W51,Cholera,"Risk 
Communication",,,,2021-12-26
"Continue  airing 
• 
of 
cholera 
jingles 
and 
distribution 
of 
IEC materials 
Continue media 
• 
engagement 
meetings and training 
of journalist, other 
media professionals 
Continued follow-up 
• 
with states for update 
on risk 
communication",Cholera,"Continue  Airing 
• 
Of 
Cholera 
Jingles 
And 
Distribution 
Of 
Iec Materials 
Continue Media 
• 
Engagement 
Meetings And Training 
Of Journalist, Other 
Media Professionals 
Continued Follow-Up 
• 
With States For Update 
On Risk 
Communication",,,,2021-10-10
" Continueairingof
cholera
j
i
ngles
anddistributionof
I
ECmaterials
 Continuemedia
engagementmeetings
andtrainingofjournalist,
othermedia
professionals
 Continuedfollow-upwith
statesforupdateonrisk
communication",Cholera," Continueairingof
Cholera
J
I
Ngles
Anddistributionof
I
Ecmaterials
 Continuemedia
Engagementmeetings
Andtrainingofjournalist,
Othermedia
Professionals
 Continuedfollow-Upwith
Statesforupdateonrisk
Communication",,,,
,Cholera,"L
O
G
I
T
I
C
S",,,,
" Continueairingof
cholera
j
i
ngles
anddistributionof
I
ECmaterials
 Continuemedia
engagementmeetings
andtrainingofjournalist,
othermedia
professionals
 Continuedfollow-upwith
statesforupdateonrisk
communication",Cholera," Cholera Jingles Are Being Aired In
Englishandlocallanguages
 Community
Social Mobilisation,
Media Interviews, Distribution Of
I
Nformation,
Education
And
Communication (Iec)Materials And
Awareness Campaigns Ongoing In
Affectedcommunities
 Conductedministerialpressbriefings",,,,
2025-W46,Cholera,Surveillance,,,,2025-11-13
2021-W35,Cholera,Surveillance,,,,2021-09-05
"Continue  airing 
• 
of 
cholera 
jingles 
and 
distribution 
of 
IEC materials 
Continue media 
• 
engagement 
meetings and training 
of journalist, other 
media professionals 
Continued follow-up 
• 
with states for update 
on risk 
communication",Cholera,"•  Cholera Jingles Are Being Aired In English 
And Local Languages 
•  Community  Social  Mobilisation,  Media 
Interviews,  Distribution  Of 
Information, 
Education 
And  Communication 
(Iec) 
Materials 
And 
Awareness 
Campaigns 
Ongoing In Affected Communities 
•  Conducted Ministerial Press Briefings",,,,2021-09-05
2021-W34,Cholera,Surveillance,,,,2021-08-29
2021-W34,Cholera,"Federal 
Ministry 
Of  Water 
Resources 
(Fmwr)  
•  Continuous  Construction  Of  Sanitation  And 
Hygiene  Facilities  With  Boreholes  In  Cholera 
Hotspots",,,,2021-08-29
2021-W34,Cholera,"Risk 
Communication",,,,2021-08-29
" Continueairingof
Cholera
j
i
ngles
anddistributionof
I
ECmaterials",Cholera," Cholera Jingles Are Being Aired In
Englishandlocallanguages
 Community
Social Mobilisation,
Media Interviews, Distribution Of",,,,
,Cholera,"S
U
R
V
E
I
L
A
N
C
E",,,,
" Continueairingof
Cholera
j
i
ngles
anddistributionof
I
ECmaterials
 Continuemedia
engagementmeetings
andtrainingofjournalist,
othermedia
professionals
 Continuedfollow-upwith
statesforupdateonrisk
communication",Cholera," Cholera Jingles Are Being Aired In
Englishandlocallanguages
 Community
Social Mobilisation,
Media Interviews, Distribution Of
I
Nformation,
Education
And
Communication (Iec)Materials And
Awareness Campaigns Ongoing In
Affectedcommunities
 Conductedministerialpressbriefings",,,,
"• 
The sample positivity rate for Mpox is 
0% and 33% for Varicella-Zoster Virus 
(VZV)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 33% For Varicella-Zoster Virus 
(Vzv)",,,,
"• 
The sample positivity rate for Mpox is 
25% and 75% for Varicella-Zoster Virus 
(VZV)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
25% And 75% For Varicella-Zoster Virus 
(Vzv)",,,,
"• 
The sample positivity rate for Mpox is 
10% and 33% for Varicella-Zoster Virus 
(VZV)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
10% And 33% For Varicella-Zoster Virus 
(Vzv)",,,,2025-04-01
"• 
The sample positivity rate for Mpox is 
0% and 61% for Varicella-Zoster Virus 
(VZV)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 61% For Varicella-Zoster Virus 
(Vzv)",,,,2025-11-20
"• 
The sample positivity rate for Mpox is 
20% and 65% for Varicella-Zoster Virus 
(VZV) 
• 
14% of samples met the target overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
20% And 65% For Varicella-Zoster Virus 
(Vzv) 
• 
14% Of Samples Met The Target Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
0% and 58% for Varicella-Zoster Virus 
(VZV) 
• 
67% of samples met the target overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 58% For Varicella-Zoster Virus 
(Vzv) 
• 
67% Of Samples Met The Target Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
0% and 63% for Varicella-Zoster Virus 
(VZV) 
• 
90% of samples met the target overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 63% For Varicella-Zoster Virus 
(Vzv) 
• 
90% Of Samples Met The Target Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,2025-11-03
"• 
The sample positivity rate for Mpox is 
3% and 43% for Varicella-Zoster Virus 
(VZV) 
• 
47% of samples met the target overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
3% And 43% For Varicella-Zoster Virus 
(Vzv) 
• 
47% Of Samples Met The Target Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
0% and 52% for Varicella-Zoster Virus 
(VZV) 
• 
53% of samples met the target overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 52% For Varicella-Zoster Virus 
(Vzv) 
• 
53% Of Samples Met The Target Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
0% and 82% for Varicella-Zoster Virus 
(VZV) 
• 
36% of samples met the target overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 82% For Varicella-Zoster Virus 
(Vzv) 
• 
36% Of Samples Met The Target Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
10% and 67% for Varicella-Zoster Virus 
(VZV) 
• 
29% of samples met the target overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
10% And 67% For Varicella-Zoster Virus 
(Vzv) 
• 
29% Of Samples Met The Target Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,2025-02-20
"• 
The sample positivity rate for Mpox is 
0% and 60% for Varicella-Zoster Virus 
(VZV) 
• 
40% of samples met the target overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 60% For Varicella-Zoster Virus 
(Vzv) 
• 
40% Of Samples Met The Target Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,2025-11-01
"• 
The sample positivity rate for Mpox is 
0% and 81% for Varicella-Zoster Virus 
(VZV) 
• 
19% of samples met the target overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 81% For Varicella-Zoster Virus 
(Vzv) 
• 
19% Of Samples Met The Target Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
0% and 50% for Varicella-Zoster Virus 
(VZV) 
• 
0% of samples met the target overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 50% For Varicella-Zoster Virus 
(Vzv) 
• 
0% Of Samples Met The Target Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
0% and 91% for Varicella-Zoster Virus 
(VZV) 
• 
40% of samples met the target overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 91% For Varicella-Zoster Virus 
(Vzv) 
• 
40% Of Samples Met The Target Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
0% and 33% for Varicella-Zoster Virus 
(VZV) 
• 
33% of samples met the target overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 33% For Varicella-Zoster Virus 
(Vzv) 
• 
33% Of Samples Met The Target Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,2025-11-12
"• 
The sample positivity rate for Mpox is 
0% and 67% for Varicella-Zoster Virus 
(VZV) 
• 
80% of samples met the target overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 67% For Varicella-Zoster Virus 
(Vzv) 
• 
80% Of Samples Met The Target Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
0% and 78% for Varicella-Zoster Virus 
(VZV) 
• 
67% of samples meet overall 
turnaround (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 78% For Varicella-Zoster Virus 
(Vzv) 
• 
67% Of Samples Meet Overall 
Turnaround (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
0% and 73% for Varicella-Zoster Virus 
(VZV) 
• 
33% of samples meet overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 73% For Varicella-Zoster Virus 
(Vzv) 
• 
33% Of Samples Meet Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,2025-11-01
"• 
The sample positivity rate for Mpox is 
0% and 63% for Varicella-Zoster Virus 
(VZV) 
• 
0% of samples meet the overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 63% For Varicella-Zoster Virus 
(Vzv) 
• 
0% Of Samples Meet The Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
0% and 50% for Varicella-Zoster Virus 
(VZV) 
• 
56% of samples meet the overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 50% For Varicella-Zoster Virus 
(Vzv) 
• 
56% Of Samples Meet The Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,2025-11-08
"• 
The sample positivity rate for Mpox is 
0% and 82% for Varicella-Zoster Virus 
(VZV) 
• 
90% of samples met the target overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 82% For Varicella-Zoster Virus 
(Vzv) 
• 
90% Of Samples Met The Target Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
0% and 59% for Varicella-Zoster Virus 
(VZV) 
• 
29% of samples meet the overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 59% For Varicella-Zoster Virus 
(Vzv) 
• 
29% Of Samples Meet The Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 0% 
and 70% for Varicella-Zoster Virus (VZV) 
• 
50% of samples meet the overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 0% 
And 70% For Varicella-Zoster Virus (Vzv) 
• 
50% Of Samples Meet The Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
0% and 33% for Varicella-Zoster Virus 
(VZV) 
• 
25% of samples meet the overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 33% For Varicella-Zoster Virus 
(Vzv) 
• 
25% Of Samples Meet The Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
0% and 80% for Varicella-Zoster Virus 
(VZV) 
• 
25% of samples meet overall 
turnaround (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 80% For Varicella-Zoster Virus 
(Vzv) 
• 
25% Of Samples Meet Overall 
Turnaround (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
0% and 29% for Varicella-Zoster Virus 
(VZV) 
• 
57% of samples met the target overall 
turnaround time (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 29% For Varicella-Zoster Virus 
(Vzv) 
• 
57% Of Samples Met The Target Overall 
Turnaround Time (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,2025-05-05
"• 
The sample positivity rate for Mpox is 
0% and 28% for Varicella-Zoster Virus 
(VZV) 
• 
55% of samples meet overall 
turnaround (time sample was 
collected from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 28% For Varicella-Zoster Virus 
(Vzv) 
• 
55% Of Samples Meet Overall 
Turnaround (Time Sample Was 
Collected From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
0.1% and 73% for Varicella-Zoster 
Virus (VZV) 
• 
77% of samples meet overall 
turnaround  (time sample was 
collected  from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0.1% And 73% For Varicella-Zoster 
Virus (Vzv) 
• 
77% Of Samples Meet Overall 
Turnaround  (Time Sample Was 
Collected  From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
0% and 81% for Varicella-Zoster Virus 
(VZV) 
• 
30% of samples meet overall 
turnaround  (time sample was 
collected  from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 81% For Varicella-Zoster Virus 
(Vzv) 
• 
30% Of Samples Meet Overall 
Turnaround  (Time Sample Was 
Collected  From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
0% and 65% for Varicella-Zoster Virus 
(VZV) 
• 
56% of samples meet overall 
turnaround  (time sample was 
collected  from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 65% For Varicella-Zoster Virus 
(Vzv) 
• 
56% Of Samples Meet Overall 
Turnaround  (Time Sample Was 
Collected  From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
6% and 72% for Varicella-Zoster Virus 
(VZV) 
• 
53% of samples meet overall 
turnaround  (time sample was 
collected  from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
6% And 72% For Varicella-Zoster Virus 
(Vzv) 
• 
53% Of Samples Meet Overall 
Turnaround  (Time Sample Was 
Collected  From The States To The Time 
When The Result Was Shared With The 
States)",,,,2029-09-13
"• 
The sample positivity rate for Mpox is 
13% and 56% for Varicella-Zoster Virus 
(VZV) 
• 
71% of samples meet overall 
turnaround  (time sample was 
collected  from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
13% And 56% For Varicella-Zoster Virus 
(Vzv) 
• 
71% Of Samples Meet Overall 
Turnaround  (Time Sample Was 
Collected  From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
11% and 79% for Varicella-Zoster Virus 
(VZV) 
• 
53% of samples meet overall 
turnaround  (time sample was 
collected  from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
11% And 79% For Varicella-Zoster Virus 
(Vzv) 
• 
53% Of Samples Meet Overall 
Turnaround  (Time Sample Was 
Collected  From The States To The Time 
When The Result Was Shared With The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
0% and 63% for Varicella-Zoster Virus 
(VZV) 
• 
70% of samples meet overall 
turnaround  (time sample was 
collected  from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 63% For Varicella-Zoster Virus 
(Vzv) 
• 
70% Of Samples Meet Overall 
Turnaround  (Time Sample Was 
Collected  From The States To The Time 
When The Result Was Shared With The 
States)",,,,2025-11-23
"• 
The sample positivity rate for Mpox is 
4% and 89% for Varicella-Zoster Virus 
(VZV) 
• 
59% of samples meet overall 
turnaround  (time sample was 
collected  from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
4% And 89% For Varicella-Zoster Virus 
(Vzv) 
• 
59% Of Samples Meet Overall 
Turnaround  (Time Sample Was 
Collected  From The States To The Time 
When The Result Was Shared With The 
States)",,,,2025-11-09
"• 
The sample positivity rate for Mpox is 
4% and 63% for Varicella-Zoster Virus 
(VZV) 
• 
58% of samples meet overall 
turnaround  (time sample was 
collected  from the States to the time 
when the result was shared with the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
4% And 63% For Varicella-Zoster Virus 
(Vzv) 
• 
58% Of Samples Meet Overall 
Turnaround  (Time Sample Was 
Collected  From The States To The Time 
When The Result Was Shared With The 
States)",,,,2025-11-23
"• 
The sample positivity rate for Mpox is 
0% and 62% for Varicella-Zoster Virus 
(VZV) 
• 
84% of samples meet overall 
turnaround  (time sample was 
collected  from the States to the time 
when the result was shared to the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
0% And 62% For Varicella-Zoster Virus 
(Vzv) 
• 
84% Of Samples Meet Overall 
Turnaround  (Time Sample Was 
Collected  From The States To The Time 
When The Result Was Shared To The 
States)",,,,2025-03-06
"• 
The sample positivity rate for Mpox is 
14% and 67% for Varicella-Zoster Virus 
(VZV) 
• 
60% of samples meet overall 
turnaround  (time sample was 
collected  from the States to the time 
when the result was shared to the 
States)",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
14% And 67% For Varicella-Zoster Virus 
(Vzv) 
• 
60% Of Samples Meet Overall 
Turnaround  (Time Sample Was 
Collected  From The States To The Time 
When The Result Was Shared To The 
States)",,,,
"• 
The sample positivity rate for Mpox is 
19% and 73% for Varicella-Zoster Virus 
(VZV) 
• 
59% of samples meet overall 
turnaround time (time sample was 
collected  from the States to the time 
when the result was shared with the 
States) 
• 
Four (4) samples tested positive for 
both Mpox and VZV 
• 
NRL Lab team were trained on the 
Mpox ELISA testing technique in 
Gambia with the support of UKHSA",Monkeypox,"• 
The Sample Positivity Rate For Mpox Is 
19% And 73% For Varicella-Zoster Virus 
(Vzv) 
• 
59% Of Samples Meet Overall 
Turnaround Time (Time Sample Was 
Collected  From The States To The Time 
When The Result Was Shared With The 
States) 
• 
Four (4) Samples Tested Positive For 
Both Mpox And Vzv 
• 
Nrl Lab Team Were Trained On The 
Mpox Elisa Testing Technique In 
Gambia With The Support Of Ukhsa",,,,
"• 
Planning workshop to finalise research 
protocol on Mpox vaccine and drug 
trials in collaboration with US CDC 
• 
Ongoing protocol development for 
four (4) Mpox research in 
collaboration with UK-PHRST",Monkeypox,"• 
Planning Workshop To Finalise Research 
Protocol On Mpox Vaccine And Drug 
Trials In Collaboration With Us Cdc 
• 
Ongoing Protocol Development For 
Four (4) Mpox Research In 
Collaboration With Uk-Phrst",,,,
"• 
Sample positivity rate for Mpox is 9% 
and 70% for Varicella-Zoster Virus 
(VZV) 
• 
55% of samples meet overall 
turnaround  (time sample collected  
from states to time result shared to 
states) 
• 
Inappropriate Mpox sample was 
received from two states (Osun and 
Cross river)",Monkeypox,"• 
Sample Positivity Rate For Mpox Is 9% 
And 70% For Varicella-Zoster Virus 
(Vzv) 
• 
55% Of Samples Meet Overall 
Turnaround  (Time Sample Collected  
From States To Time Result Shared To 
States) 
• 
Inappropriate Mpox Sample Was 
Received From Two States (Osun And 
Cross River)",,,,2025-11-01
"• 
Planning Mpox Webinar for a scientific 
audience 
• 
Sharing of Social Behavioural 
Change(SBC) materials (Soft copy 
posters, Hand bills, FAQs and social 
media artboards)",Monkeypox,"• 
Planning Mpox Webinar For A Scientific 
Audience 
• 
Sharing Of Social Behavioural 
Change(Sbc) Materials (Soft Copy 
Posters, Hand Bills, Faqs And Social 
Media Artboards)",,,,2025-11-01
2025-W44,Monkeypox,"•  Mpox Clade Ii Is The Circulating Strain 
In Nigeria 
• 
Planning A Mpox Vaccine And Drug 
Trail In Collaboration With Us Cdc 
• 
Ongoing Four (4) Research 
Collaboration With Uk-Phrst 
(Seroprevalence, Social Science, 
Household/One Health And Clinicals)",,,,2025-11-01
"• 
Dissemination of Social Behavioural 
Change(SBC) materials (Soft copy 
posters, Hand bills, FAQs and social 
media artboards) in English, pidgin, 
hausa, yoruba and igbo.",Monkeypox,"• 
Dissemination Of Social Behavioural 
Change(Sbc) Materials (Soft Copy 
Posters, Hand Bills, Faqs And Social 
Media Artboards) In English, Pidgin, 
Hausa, Yoruba And Igbo.",,,,
"• 
Sample positivity rate for Mpox is 8% 
and 50% for Varicella-Zoster Virus 
(VZV) 
• 
42% of samples meet overall 
turnaround  (time sample collected  
from states to time result shared to 
states) 
• 
One sample tested positive for both 
Mpox and VZV 
• 
Poor sample management was 
observed in samples from three states",Monkeypox,"• 
Train Reporting States On 
Appropriate Mpox Sample 
Collection, Techniques , 
Packaging And Transportation",,,,2025-06-01
"• 
Fatigue, general weakness, fever and 
vesiculopustular rash are some of the 
symptoms recorded from reporting 
states 
• 
Case fatality Rate (CFR) is 4% (week 1 
to week 9)",Monkeypox,"• 
Train Reporting States On 
Appropriate Mpox Sample 
Collection, Techniques , 
Packaging And Transportation.",,,,2025-06-01
"• 
Nigeria has the highest burden of 
Mpox cases in Africa (57%) with a CFR 
of (1%)",Monkeypox,"• 
Assessment For Hiv, Other Stis 
And Cd4 Cell Counts In Every",,,,2025-06-01
,Monkeypox,"• 
Train States On Appropriate Mpox 
Sample Management",,,,
,Monkeypox,"• 
Planning To Conduct Hcd And Sbc 
Activities In Selected States 
• 
Conduct Mpox Situation Update 
Webinar",,,,
,Monkeypox,"• 
Finalize Protocol Development 
• 
Implementation Of Mpox Research 
Projects",,,,
"• 
Sample positivity rate for Mpox is 9% and 
74% for Varicella-zoster virus (VZV) 
• 
42% of samples meet overall turnaround  
(time sample collected  from states to time 
result shared to states) 
• 
Poor sample management observed from 
two states (Plateau and Imo)",Monkeypox,"• 
Train States On Appropriate Mpox 
Sample Collection Techniques, 
Sample Packaging And Transport",,,,
"• 
Ongoing dissemination of Mpox SBCC 
materials 
• 
Airing of Mpox jingles in Lagos and FCT 
with the support of BA-N  
• 
Mpox content development for the 
animal sector with the support of BA-N 
and FAO",Monkeypox,"• 
Continue To Engage With The 
Public Via Ncdc Social Media 
With Key Messages On Mpox",,,,
"• 
Planning a workshop to finalise the 
protocol development for an Mpox 
clinical trial",Monkeypox,•,,,,
2025-W45,Monkeypox,"• 
Assist States In Adopting An 
Integrated Risk Communication 
Approach  (One Health) In Response 
To Mpox Outbreak",,,,2025-11-08
2025-W45,Monkeypox,Research,,,,2025-11-08
"• 
Current sample positivity rate for 
Mpox is 6% and 83% for Varicella-
zoster virus (VZV) 
• 
Conducted retrospective HIV testing 
for 915 Mpox samples from 2022: 
6.5% positivity for HIV only and 5% 
positivity for Mpox and HIV co-
infection  
• 
79% of samples met overall 
turnaround (time sample collected 
from states to time result shared to 
states)",Monkeypox,"• 
Test All The Remaining Samples For 
In 2022 And 2023 For Hiv Infection",,,,
"• 
Analysed 987 Mpox related 
conversations on social media 
platforms: message saturation, 
mistrust in data, and disbelief in the 
disease were the three main themes 
that emerged",Monkeypox,"• 
Plan For A National Perception 
Survey 
• 
Engage States On Strategies To 
Mitigate Infodemics Detected 
• 
Update And Disseminate Public 
Health Advisory Addressing 
Identified Misinformation",,,,
"• 
Nigeria has the highest number of 
confirmed Mpox cases and the 4th 
highest case fatality ratio (0.9%) 
• 
In Italy, Mpox virus DNA was detected 
in wastewater from the largest Italian 
airport in Rome using real-time PCR 
assays",Monkeypox,"• 
Plan To Commence Wastewater 
Surveillance -As One Of The 
Approaches To Mpox Detection 
And Prevention",,,,
"• 
Reviewing the Mpox IPC guidelines for 
home care",Monkeypox,"• 
Finalize Ipc Iec Materials In 
Collaboration With Ba-N, Mtaps And 
Risk Comms Pillar",,,,2025-11-04
"• 
Airing jingles in Lagos and FCT",Monkeypox,"• 
Continue To Engage With The Public 
Via Ncdc Social Media With Key 
Messages On Mpox",,,,2025-11-04
"• 
Conducted IPC training for 30 IPC focal 
persons from secondary and tertiary 
health facilities in Bauchi state 
• 
Finalised plans for starting multimodal 
hand hygiene improvement program 
across 30 HFs in FCT and Nasarawa 
state. 
• 
Finalised mpox IPC guidelines, home-
based care and management.",Monkeypox,"• 
Finalisation Of Graphic Design And 
Technical Content For Ipc Iec 
Materials Co-Developed With Ba-N 
And Risk Comm Pillar Ongoing",,,,
2025-W45,Monkeypox,"• 
Participated At The Avohc-Surge 
Training Delivered By The Fmoh, 
Africa Cdc And Who-Afro – 84 
Participants Trained On Rapid 
Response As Part Of The Public Health 
Workforce Training On Responding To 
All Hazards Including Mpox 
• 
Review Of The Mpox Ipc Guidelines 
Ongoing 
• 
Reviewed Ipc Iec Materials Co-
Developed With The Risk 
Communications Pillar, Breakthrough 
Action Nigeria And Usaid",,,,2025-11-07
2025-W45,Monkeypox,"• 
Developed The First Draft Of The Mpox 
Home Management Protocol",,,,2025-11-07
2025-W45,Monkeypox,"• 
Procured Reagents For Hiv Testing 
• 
Ongoing Sequencing Of Mpox 
Samples To Define The Circulating 
Clade",,,,2025-11-07
"• 
Train selected states (including Zamfara) 
on appropriate sample selection, 
collection techniques, sample packaging 
and transport",Monkeypox,"• 
Train Selected States (Including Zamfara) 
On Appropriate Sample Selection, 
Collection Techniques, Sample Packaging 
And Transport",,,,
"•  Mpox and VZV reagents have been 
procured and successfully validated 
and sent to National Reference and sh 
Central Public Health Laboratories",Monkeypox,"•  Mpox And Vzv Reagents Have Been 
Procured And Successfully Validated 
And Sent To National Reference And Sh 
Central Public Health Laboratories",,,,2025-11-05
"• 
Sequencing one hundred and ninety-
two Mpox samples to define xxxx 
ongoing 
• 
Received reagents for routine Mpx 
testing",Monkeypox,"• 
Train States On Appropriate Sample 
Collection Techniques , Sample 
Packaging And Transport",,,,
,Monkeypox,"• 
Retrieved And Tested 59 Pending 
Samples From National Reference And 
Central Public Health Labooratories 
• 
Followed Up With States That Had 
Challenges With Sample Management",,,,
"1. Dissemination of Monkeypox advisory to IPC 
focal persons under the Orange Network 
2. Engagement meeting with the CM pillar on 
harmonizing IPC and CM guidelines for MPX  
3. Review of the timelines and relevant 
indicators in the approved MPX IAP 
4. Mentorship support and provision of 
technical IPC materials on MPX to Rivers, 
Ogun, and Taraba states IPC pillars 
5. MPX HCW infection surveillance continues 
across the Orange Network and states",Monkeypox,"1. Continue Ipc Mentoring 
Engagements Across States 
2. Continue To Provide Close-Level 
Support To States Who Have Activated 
The Mpx Eoc 
3. Further Dissemination Of Monkeypox 
Advisories Across Ipc Networks At 
State And Health Facilities 
4. Continuous Support To State And 
Facilities On Ipc Program 
Establishment/Strengthening  
5. Review And Finalization Workshop On 
Mpx Ipc Guidelines With Relevant 
Stakeholders 
6. Implementation Of Other Approved 
Ipc Activities In The Mpx Iap",,,,
"1.  Continue IPC mentoring 
engagements across states 
2.  Continue to provide close-
level support to states who 
have activated the MPX EOC 
3.  Further dissemination of 
Monkeypox advisories across 
IPC networks at State and 
Health facilities",Monkeypox,"1.  Continue Ipc Mentoring 
Engagements Across States 
2.  Continue To Provide Close-
Level Support To States Who 
Have Activated The Mpx Eoc 
3.  Further Dissemination Of 
Monkeypox Advisories Across 
Ipc Networks At State And 
Health Facilities",,,,2025-11-03
"1.  Continue IPC mentoring 
engagements across 
states 
2.  Continue to provide 
close-level support to 
states who have activated 
the MPX EOC 
3. 
Further dissemination of 
Monkeypox advisories 
across IPC networks at 
State and Health facilities",Monkeypox,"1.  Continue Ipc Mentoring 
Engagements Across 
States 
2.  Continue To Provide 
Close-Level Support To 
States Who Have Activated 
The Mpx Eoc 
3. 
Further Dissemination Of 
Monkeypox Advisories 
Across Ipc Networks At 
State And Health Facilities",,,,
"Continue IPC mentoring 
engagements across states 
Continue to provide close-level 
support to states who have 
activated the MPX EOC 
Further dissemination of 
Monkeypox advisories across IPC 
networks at State and Health 
facilities",Monkeypox,"Continue Ipc Mentoring 
Engagements Across States 
Continue To Provide Close-Level 
Support To States Who Have 
Activated The Mpx Eoc 
Further Dissemination Of 
Monkeypox Advisories Across Ipc 
Networks At State And Health 
Facilities",,,,
"F
Continue IPC mentoring 
engagements across states 
urther dissemination of Monkey 
Pox advisories across IPC 
networks at State and Health 
facilities",Monkeypox,"F
Continue Ipc Mentoring 
Engagements Across States 
Urther Dissemination Of Monkey 
Pox Advisories Across Ipc 
Networks At State And Health 
Facilities",,,,
"Africa Centre for Disease Control 
(ACDC) is supporting NRL on 
regional training for African 
countries on Monkeypox virus 
detection using RT-PCR and MPX 
viral genomics.  
Genomic sequencing  ongoing 
Ongoing plans to validate more 
test kits",Monkeypox,"Africa Centre For Disease Control 
(Acdc) Is Supporting Nrl On 
Regional Training For African 
Countries On Monkeypox Virus 
Detection Using Rt-Pcr And Mpx 
Viral Genomics.  
Genomic Sequencing  Ongoing 
Ongoing Plans To Validate More 
Test Kits",,,,
"Ongoing plans to validate more 
test kits 
Africa Centre for Disease Control 
(ACDC) is supporting NRL on 
regional training for African 
countries on Monkeypox virus 
detection using RT-PCR and MPX 
viral genomics.  
Publication of genomic 
sequencing data ongoing",Monkeypox,"Ongoing Plans To Validate More 
Test Kits 
Africa Centre For Disease Control 
(Acdc) Is Supporting Nrl On 
Regional Training For African 
Countries On Monkeypox Virus 
Detection Using Rt-Pcr And Mpx 
Viral Genomics.  
Publication Of Genomic 
Sequencing Data Ongoing",,,,
"Development and airing of jingles 
on National TV",Monkeypox,"Development And Airing Of Jingles 
On National Tv",,,,
,Monkeypox,"Currently Conducting Baseline Survey To 
Understand Nigeria’S Knowledge, Attitude And 
Practices To Monkeypox",,,,
2025-W47,Monkeypox,"Off-Site Support To States  
Continous Testing Of Samples",,,,2025-11-17
2025-W45,Yellow Fever,"•  Of The 83 Samples Collected, 25 (30.1%) Had Tested Positive For Yellow Fever.",,,,2025-11-04
2010-W08,Yellow Fever,From Bauchi (8Th November) Were Confirmed As Yellow Fever With Pcr At,,,,2010-02-24
2010-W08,Yellow Fever,"▪  On 7Th Of November, The National Yellow Fever Emergency Operations",,,,2010-02-24
"Figure 2: Map of Nigeria showing states and LGAs with yellow fever outbreak, epi-week 24 – 45, 2020",Yellow Fever,"Figure 2: Map Of Nigeria Showing States And Lgas With Yellow Fever Outbreak, Epi-Week 24 – 45, 2020",,,,2010-02-24
,Measles,"46.2 
128.9 
66.8 
54.0 
63.1 
< 1/Million 
Annualized Measles Incidence 
Population",,,,
,Measles,"2.0 
4.2 
3.2 
Annualized Non-Measles Febrile Rash 
≥ 2/100,000 
Illness (Nmfri) Rate 
Population",,,,
2025-W10,Measles,"58.1 
170.6 
86.3 
71.2 
38.8 
< 1/Million 
Annualized Measles Incidence 
Population",,,,2025-03-05
2025-W10,Measles,"2.5 
5.5 
4.2 
Annualized Non-Measles Febrile Rash 
≥ 2/100,000 
Illness (Nmfri) Rate 
Population",,,,2025-03-05
,Measles,"78 
19 
13 
•  # Of Lgas With Measles Outbreak 
•  # Of States With At Least 1 Lga With Measles 
24 
11 + Fct 
8 
Outbreak",,,,
,Measles,"- 
228 
157 
•  # Of Lgas With Measles Outbreak 
•  # Of States With At Least 1 Lga With Measles 
- 
33 +Fct 
33+ Fct 
Outbreak",,,,
,Measles,"- 
218 
110 
•  # Of Lgas With Measles Outbreak 
•  # Of States With At Least 1 Lga With Measles 
- 
33 +Fct 
23 + Fct 
Outbreak",,,,
2025-W01,Measles,# Of Measles Outbreak (Source: Lab Data),,,,2025-01-05
2025-W01,Measles,"109 
208 
223 
•  # Of Lgas With Measles Outbreak 
•  # Of States With At Least 1 Lga With Measles 
22 + Fct 
33 +Fct 
32 + Fct 
Outbreak",,,,2025-01-05
,Measles,"105 
203 
222 
  # Of Lgas With Measles Outbreak 
22 + Fct 
33 +Fct 
32 + Fct 
  # Of States With At Least 1 Lga With Measles Outbreak",,,,
,Measles,"100 
192 
229 
  # Of Lgas With Measles Outbreak 
19 
30 +Fct 
32 + Fct 
  # Of States With At Least 1 Lga With Measles Outbreak",,,,
,Measles,# Of Measles Outbreak (Source: Lab Data),,,,
,Measles,"97 
179 
228 
  # Of Lgas With Measles Outbreak 
19 
29 +Fct 
32 + Fct 
  # Of States With At Least 1 Lga With Measles Outbreak",,,,
,Malaria,Symptoms,,,,
2020-W01,COVID-19,Kano,77.0,1.0,1.3,2020-01-01
2020-W01,COVID-19,Borno,30.0,2.0,6.67,2020-01-01
2020-W01,COVID-19,Gombe,30.0,0.0,0.0,2020-01-01
2020-W01,COVID-19,Katsina,30.0,1.0,3.33,2020-01-01
2020-W01,COVID-19,"Akwa 
Ibom",11.0,1.0,9.09,2020-01-01
2020-W01,COVID-19,Kwara,11.0,0.0,0.0,2020-01-01
2020-W01,COVID-19,Delta,6.0,1.0,16.67,2020-01-01
2020-W01,COVID-19,Abia,2.0,0.0,0.0,2020-01-01
2020-W01,COVID-19,Jigawa,2.0,0.0,0.0,2020-01-01
2020-W01,COVID-19,Niger,2.0,0.0,0.0,2020-01-01
2020-W01,COVID-19,Sokoto,2.0,0.0,0.0,2020-01-01
2020-W01,COVID-19,Zamfara,2.0,0.0,0.0,2020-01-01
2020-W01,COVID-19,Adamawa,1.0,0.0,0.0,2020-01-01
2020-W01,COVID-19,Anambra,1.0,0.0,0.0,2020-01-01
2020-W01,COVID-19,Imo,1.0,0.0,0.0,2020-01-01
2020-W01,COVID-19,Plateau,1.0,0.0,0.0,2020-01-01
,COVID-19,Zamfara,2.0,0.0,0.0,
,COVID-19,Plateau,1.0,0.0,0.0,
2025-W46,COVID-19,Lagos,582.0,16.0,2.75,2025-11-12
2025-W46,COVID-19,Abuja,133.0,3.0,2.26,2025-11-12
2025-W46,COVID-19,Kano,73.0,1.0,1.37,2025-11-12
2025-W46,COVID-19,Ogun,29.0,1.0,3.45,2025-11-12
2025-W46,COVID-19,Katsina,21.0,1.0,4.76,2025-11-12
2025-W46,COVID-19,Osun,20.0,0.0,0.0,2025-11-12
2025-W46,COVID-19,Oyo,17.0,1.0,5.88,2025-11-12
2025-W46,COVID-19,Edo,17.0,2.0,11.76,2025-11-12
2025-W46,COVID-19,Borno,12.0,2.0,16.67,2025-11-12
2025-W46,COVID-19,Kwara,11.0,0.0,0.0,2025-11-12
2025-W46,COVID-19,"Akwa 
Ibom",11.0,1.0,9.09,2025-11-12
2025-W46,COVID-19,Kaduna,9.0,0.0,0.0,2025-11-12
2025-W46,COVID-19,Gombe,9.0,0.0,0.0,2025-11-12
2025-W46,COVID-19,Bauchi,8.0,0.0,0.0,2025-11-12
2025-W46,COVID-19,Delta,6.0,1.0,16.67,2025-11-12
2025-W46,COVID-19,Ekiti,4.0,1.0,25.0,2025-11-12
2025-W46,COVID-19,Ondo,3.0,0.0,0.0,2025-11-12
2025-W46,COVID-19,Rivers,3.0,1.0,33.33,2025-11-12
2025-W46,COVID-19,Niger,2.0,0.0,0.0,2025-11-12
2025-W46,COVID-19,Enugu,2.0,0.0,0.0,2025-11-12
2025-W46,COVID-19,Jigawa,2.0,0.0,0.0,2025-11-12
2025-W46,COVID-19,Abia,2.0,0.0,0.0,2025-11-12
2025-W46,COVID-19,Benue,1.0,0.0,0.0,2025-11-12
2025-W46,COVID-19,Anambra,1.0,0.0,0.0,2025-11-12
2025-W46,COVID-19,Sokoto,1.0,0.0,0.0,2025-11-12
2025-W46,COVID-19,Adamawa,1.0,0.0,0.0,2025-11-12
2025-W46,COVID-19,Plateau,1.0,0.0,0.0,2025-11-12
,COVID-19,Adamawa,1.0,0.0,0.0,
,COVID-19,Katsina,12.0,1.0,8.33,
,COVID-19,Kwara,9.0,0.0,0.0,
,COVID-19,"Akwa 
Ibom",9.0,1.0,11.11,
,COVID-19,Gombe,5.0,0.0,0.0,
,COVID-19,Delta,4.0,1.0,25.0,
,COVID-19,Ondo,3.0,0.0,0.0,
,COVID-19,Borno,3.0,1.0,33.33,
,COVID-19,Niger,2.0,0.0,0.0,
,COVID-19,Jigawa,2.0,0.0,0.0,
,COVID-19,Abia,2.0,0.0,0.0,
,COVID-19,Anambra,1.0,0.0,0.0,
,COVID-19,Sokoto,1.0,0.0,0.0,
2025-W45,COVID-19,Osun,20.0,0.0,0.0,2025-11-04
2025-W45,COVID-19,Oyo,9.0,0.0,0.0,2025-11-04
2025-W45,COVID-19,Bauchi,6.0,0.0,0.0,2025-11-04
2025-W45,COVID-19,Akwa Ibom,5.0,0.0,0.0,2025-11-04
2025-W45,COVID-19,Kaduna,5.0,0.0,0.0,2025-11-04
2025-W45,COVID-19,Ekiti,2.0,0.0,0.0,2025-11-04
2025-W45,COVID-19,Benue,1.0,0.0,0.0,2025-11-04
2025-W45,COVID-19,Ondo,1.0,0.0,0.0,2025-11-04
2025-W10,COVID-19,Lagos,109.0,1.0,0.92,2025-03-04
2025-W10,COVID-19,Abuja,43.0,2.0,4.65,2025-03-04
2025-W10,COVID-19,Osun,20.0,0.0,0.0,2025-03-04
2025-W10,COVID-19,Oyo,9.0,0.0,0.0,2025-03-04
2025-W10,COVID-19,Edo,7.0,1.0,14.29,2025-03-04
2025-W10,COVID-19,Bauchi,6.0,0.0,0.0,2025-03-04
2025-W10,COVID-19,Akwa Ibom,5.0,0.0,0.0,2025-03-04
2025-W10,COVID-19,Ogun,4.0,0.0,0.0,2025-03-04
2025-W10,COVID-19,Kaduna,4.0,0.0,0.0,2025-03-04
2025-W10,COVID-19,Enugu,2.0,0.0,0.0,2025-03-04
2025-W10,COVID-19,Ekiti,2.0,0.0,0.0,2025-03-04
2025-W10,COVID-19,Benue,1.0,0.0,0.0,2025-03-04
2025-W10,COVID-19,Rivers,1.0,0.0,0.0,2025-03-04
2025-W10,COVID-19,Ondo,1.0,0.0,0.0,2025-03-04
2020-W01,COVID-19,Lagos,109.0,1.0,0.92,2020-01-02
2020-W01,COVID-19,Abuja,41.0,2.0,4.88,2020-01-02
2020-W01,COVID-19,Osun,22.0,0.0,0.0,2020-01-02
2020-W01,COVID-19,Oyo,8.0,0.0,0.0,2020-01-02
2020-W01,COVID-19,Akwa Ibom,5.0,0.0,0.0,2020-01-02
2020-W01,COVID-19,Ogun,4.0,0.0,0.0,2020-01-02
2020-W01,COVID-19,Kaduna,4.0,0.0,0.0,2020-01-02
2020-W01,COVID-19,Edo,7.0,1.0,14.29,2020-01-02
2020-W01,COVID-19,Bauchi,3.0,0.0,0.0,2020-01-02
2020-W01,COVID-19,Enugu,2.0,0.0,0.0,2020-01-02
2020-W01,COVID-19,Ekiti,2.0,0.0,0.0,2020-01-02
2020-W01,COVID-19,Benue,1.0,0.0,0.0,2020-01-02
2020-W01,COVID-19,Rivers,1.0,0.0,0.0,2020-01-02
2020-W01,COVID-19,Ondo,1.0,0.0,0.0,2020-01-02
,COVID-19,Akwa Ibom,5.0,0.0,0.0,
,COVID-19,"Covid-19 Situation Report  
 
  
    
  Major Response Activities 
• 
• 
• 
• 
• 
 
3 | P A G E",,,,
,COVID-19,Oyo,7.0,0.0,0.0,
,COVID-19,Bauchi,2.0,0.0,0.0,
,COVID-19,Enugu,2.0,0.0,0.0,
,COVID-19,Osun,2.0,0.0,0.0,
,COVID-19,Benue,1.0,0.0,0.0,
,COVID-19,Ekiti,1.0,0.0,0.0,
,COVID-19,Kaduna,1.0,0.0,0.0,
2025-W44,COVID-19,Osun,2.0,0.0,0.0,2025-11-02
2025-W44,COVID-19,Benue,1.0,0.0,0.0,2025-11-02
2025-W44,COVID-19,Kaduna,1.0,0.0,0.0,2025-11-02
2025-W36,COVID-19,Jigawa,0.0,0.0,,2025-09-06
2025-W36,COVID-19,Kaduna,0.0,0.0,,2025-09-06
2025-W36,COVID-19,Kebbi,0.0,0.0,,2025-09-06
2025-W36,COVID-19,Osun,1.0,0.0,0.0,2025-09-06
2025-W36,COVID-19,Sokoto,0.0,0.0,,2025-09-06
2025-W30,COVID-19,A/Ibom,0.0,0.0,,2025-07-24
2025-W30,COVID-19,Adamawa,0.0,0.0,,2025-07-24
2025-W30,COVID-19,Bauchi,1.0,0.0,0.0,2025-07-24
2025-W30,COVID-19,Bayelsa,0.0,0.0,,2025-07-24
2025-W30,COVID-19,Cross River,0.0,0.0,,2025-07-24
2025-W30,COVID-19,Delta,0.0,0.0,,2025-07-24
2025-W30,COVID-19,Ebonyi,0.0,0.0,,2025-07-24
2025-W30,COVID-19,Edo,1.0,0.0,0.0,2025-07-24
2025-W30,COVID-19,Ekiti,1.0,0.0,0.0,2025-07-24
2025-W30,COVID-19,Enugu,0.0,0.0,,2025-07-24
2025-W30,COVID-19,Abuja,10.0,1.0,10.0,2025-07-24
2025-W30,COVID-19,Kano,0.0,0.0,,2025-07-24
2025-W30,COVID-19,Katsina,0.0,0.0,,2025-07-24
2025-W30,COVID-19,Kebbi,0.0,0.0,,2025-07-24
2025-W30,COVID-19,Lagos,32.0,0.0,0.0,2025-07-24
2025-W30,COVID-19,Nasarawa,0.0,0.0,,2025-07-24
2025-W30,COVID-19,Ogun,3.0,0.0,0.0,2025-07-24
2025-W30,COVID-19,Ondo,0.0,0.0,,2025-07-24
2025-W30,COVID-19,Osun,1.0,0.0,0.0,2025-07-24
2025-W30,COVID-19,Oyo,1.0,0.0,0.0,2025-07-24
2025-W30,COVID-19,Plateau,0.0,0.0,,2025-07-24
2025-W30,COVID-19,Rivers,1.0,0.0,0.0,2025-07-24
2025-W30,COVID-19,Sokoto,0.0,0.0,,2025-07-24
2025-W30,COVID-19,Yobe,0.0,0.0,,2025-07-24
2025-W44,COVID-19,A/Ibom,0.0,0.0,,2025-11-02
2025-W44,COVID-19,Adamawa,0.0,0.0,,2025-11-02
2025-W44,COVID-19,Bauchi,1.0,0.0,0.0,2025-11-02
2025-W44,COVID-19,Bayelsa,0.0,0.0,,2025-11-02
2025-W44,COVID-19,Cross River,0.0,0.0,,2025-11-02
2025-W44,COVID-19,Delta,0.0,0.0,,2025-11-02
2025-W44,COVID-19,Ebonyi,0.0,0.0,,2025-11-02
2025-W44,COVID-19,Edo,1.0,0.0,0.0,2025-11-02
2025-W44,COVID-19,Ekiti,1.0,0.0,0.0,2025-11-02
2025-W44,COVID-19,Enugu,0.0,0.0,,2025-11-02
2025-W44,COVID-19,Abuja,8.0,1.0,12.5,2025-11-02
2025-W44,COVID-19,Kano,0.0,0.0,,2025-11-02
2025-W44,COVID-19,Katsina,0.0,0.0,,2025-11-02
2025-W44,COVID-19,Lagos,29.0,0.0,0.0,2025-11-02
2025-W44,COVID-19,Nasarawa,0.0,0.0,,2025-11-02
2025-W44,COVID-19,Ogun,3.0,0.0,0.0,2025-11-02
2025-W44,COVID-19,Ondo,0.0,0.0,,2025-11-02
2025-W44,COVID-19,Oyo,1.0,0.0,0.0,2025-11-02
2025-W44,COVID-19,Plateau,0.0,0.0,,2025-11-02
2025-W44,COVID-19,Rivers,0.0,0.0,,2025-11-02
2025-W44,COVID-19,Yobe,0.0,0.0,,2025-11-02
2025-W36,COVID-19,Adamawa,0.0,0.0,,2025-09-06
2025-W36,COVID-19,Bauchi,0.0,0.0,,2025-09-06
2025-W36,COVID-19,Bayelsa,0.0,0.0,,2025-09-06
2025-W36,COVID-19,Cross River,0.0,0.0,,2025-09-06
2025-W36,COVID-19,Delta,0.0,0.0,,2025-09-06
2025-W36,COVID-19,Ebonyi,0.0,0.0,,2025-09-06
2025-W36,COVID-19,Oyo,1.0,0.0,0.0,2025-09-06
2025-W36,COVID-19,Plateau,0.0,0.0,,2025-09-06
2025-W36,COVID-19,A/Ibom,0.0,0.0,,2025-09-06
2025-W36,COVID-19,Nasarawa,0.0,0.0,,2025-09-06
2025-W36,COVID-19,Ekiti,1.0,0.0,0.0,2025-09-06
2025-W36,COVID-19,Katsina,0.0,0.0,,2025-09-06
2025-W36,COVID-19,Ondo,0.0,0.0,,2025-09-06
2025-W36,COVID-19,Edo,0.0,,,2025-09-06
2025-W36,COVID-19,Enugu,0.0,,,2025-09-06
2025-W36,COVID-19,Abuja,0.0,,,2025-09-06
2025-W36,COVID-19,Kano,0.0,,,2025-09-06
2025-W36,COVID-19,Lagos,0.0,0.0,,2025-09-06
2025-W36,COVID-19,Ogun,0.0,1.0,,2025-09-06
2025-W36,COVID-19,Rivers,0.0,,,2025-09-06
2025-W36,COVID-19,Yobe,0.0,,,2025-09-06
2025-W45,COVID-19,Edo,0.0,0.0,,2025-11-07
2025-W45,COVID-19,Enugu,0.0,0.0,,2025-11-07
2025-W45,COVID-19,Abuja,0.0,0.0,,2025-11-07
2025-W45,COVID-19,Kano,0.0,0.0,,2025-11-07
2025-W45,COVID-19,Lagos,0.0,0.0,,2025-11-07
2025-W45,COVID-19,Ogun,0.0,0.0,,2025-11-07
2025-W45,COVID-19,Rivers,0.0,0.0,,2025-11-07
2025-W45,COVID-19,Yobe,0.0,0.0,,2025-11-07
2025-W48,COVID-19,Edo,0.0,0.0,,2025-11-30
2025-W48,COVID-19,Abuja,0.0,0.0,,2025-11-30
2025-W48,COVID-19,Kano,0.0,0.0,,2025-11-30
2025-W48,COVID-19,Lagos,0.0,0.0,,2025-11-30
2025-W48,COVID-19,Ogun,0.0,0.0,,2025-11-30
2025-W48,COVID-19,Rivers,0.0,0.0,,2025-11-30
2025-W48,COVID-19,Yobe,0.0,0.0,,2025-11-30
,COVID-19,Rivers,0.0,0.0,,
,COVID-19,Yobe,0.0,0.0,,
,COVID-19,Abuja,7.0,0.0,0.0,
,COVID-19,Kano,1.0,0.0,0.0,
,COVID-19,Edo,1.0,0.0,0.0,
,COVID-19,Ogun,1.0,0.0,0.0,
,COVID-19,Lagos,0.0,0.0,,
